Source comparison
Thymosin Alpha-1 EBV Research: Comparison of Clinical Protocols
Chronic Active EBV (adults) 1.6 mg SC twice weekly × 12 weeks ≥50% reduction in EBV-DNA 67% at 6 months −1.2 log copies/mL Best evidence for sustained viral suppression in immunocompetent adults with CAEBV Paediatric CAEBV with HLH 1.6 mg SC twice weekly × 24
This comparison does not assign a generated winner or score.
- Chronic Active EBV (adults)
- 1.6 mg SC twice weekly × 12 weeks
- ≥50% reduction in EBV-DNA
- 67% at 6 months
- −1.2 log copies/mL
- Best evidence for sustained viral suppression in immunocompetent adults with CAEBV
- Paediatric CAEBV with HLH
- 1.6 mg SC twice weekly × 24 weeks (adjunct to chemo)
- Time to lymphocyte recovery
- 72% faster recovery
- −0.8 log copies/mL
- Accelerates immune reconstitution but requires combination therapy in HLH settings
- Post-transplant EBV reactivation
- 1.6 mg SC twice weekly × 8 weeks
- Prevention of PTLD progression
- 54% remained asymptomatic
- Not consistently measured
- Limited data; most useful as bridge therapy during immunosuppression taper
- EBV-positive lymphoma (investigational)
- 3.2 mg SC twice weekly × 16 weeks
- Tumour response rate
- 18% partial response
- Variable
- Insufficient evidence as monotherapy; mechanism suggests potential in combination with checkpoint inhibitors